​
​

Collegium Pharmaceutical (COLL) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Collegium Pharmaceutical Revenue Highlights

Latest Revenue (Y)

$566.77M

Latest Revenue (Q)

$159.30M

Main Segment (Y)

Belbuca

Collegium Pharmaceutical Revenue by Period

Collegium Pharmaceutical Revenue by Year

DateRevenueChange
2023-12-31$566.77M22.17%
2022-12-31$463.93M67.56%
2021-12-31$276.87M-10.69%
2020-12-31$310.02M4.49%
2019-12-31$296.70M5.81%
2018-12-31$280.41M884.73%
2017-12-31$28.48M1564.29%
2016-12-31$1.71M100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31--

Collegium Pharmaceutical generated $566.77M in revenue during NA 2023, up 22.17% compared to the previous quarter, and up 202.12% compared to the same period a year ago.

Collegium Pharmaceutical Revenue by Quarter

DateRevenueChange
2024-09-30$159.30M9.65%
2024-06-30$145.28M0.24%
2024-03-31$144.92M-3.22%
2023-12-31$149.75M9.54%
2023-09-30$136.71M0.86%
2023-06-30$135.55M-6.37%
2023-03-31$144.77M11.69%
2022-12-31$129.62M2.05%
2022-09-30$127.01M2.80%
2022-06-30$123.55M47.52%
2022-03-31$83.75M206.09%
2021-12-31$27.36M-65.30%
2021-09-30$78.84M-4.94%
2021-06-30$82.94M-5.45%
2021-03-31$87.72M15.01%
2020-12-31$76.27M-3.67%
2020-09-30$79.18M1.43%
2020-06-30$78.06M2.02%
2020-03-31$76.51M3.11%
2019-12-31$74.20M1.73%
2019-09-30$72.94M-2.80%
2019-06-30$75.04M0.70%
2019-03-31$74.52M1.48%
2018-12-31$73.43M4.63%
2018-09-30$70.18M-3.95%
2018-06-30$73.06M14.61%
2018-03-31$63.75M490.60%
2017-12-31$10.79M-9.67%
2017-09-30$11.95M235.67%
2017-06-30$3.56M63.90%
2017-03-31$2.17M66.69%
2016-12-31$1.30M219.36%
2016-09-30$408.00K100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31--

Collegium Pharmaceutical generated $159.30M in revenue during Q3 2024, up 9.65% compared to the previous quarter, and up 117.53% compared to the same period a year ago.

Collegium Pharmaceutical Revenue Breakdown

Collegium Pharmaceutical Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Nucynta IR$108.15M$112.06M$102.22M--
Symproic$16.50M$12.27M---
Xtampza ER$177.37M$138.80M$103.71M--
Belbuca$182.09M$126.46M---
Nucynta ER$82.65M$72.42M$70.94M--
Other-$1.93M---
Nucynta Products--$173.16M--
Xtampza---$127.98M$105.01M
Nucynta Er---$65.71M$74.01M
Nucynta Ir---$116.32M$117.68M
Nucynta---$182.03M$191.69M

Collegium Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Belbuca (32.13%), Xtampza ER (31.30%), Nucynta IR (19.08%), Nucynta ER (14.58%), and Symproic (2.91%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Sep 19Jun 19Mar 19
Nucynta ER$19.77M$19.19M$42.35M$19.17M$21.14M$18.95M$17.13M$17.08M$19.26M$8.73M----------
Xtampza ER$49.49M$45.81M$88.26M$41.24M$47.87M$35.24M$38.86M$33.19M$31.52M-----------
Symproic$3.52M$3.30M$9.01M$3.84M$3.65M$4.53M$3.58M$3.86M$300.00K-----------
Nucynta IR$25.36M$25.96M$52.09M$28.16M$27.90M$28.89M$27.27M$26.55M$29.34M$13.37M----------
Belbuca$53.20M$50.66M$94.75M$43.14M$44.21M$42.05M$38.80M$42.30M$3.31M-----------
Other-----$320.00K$1.15M$458.00K------------
Elyxyb------$218.00K$109.00K$25.00K-----------
Nucynta----------$48.83M$49.92M$52.31M$45.48M$47.05M$44.50M$45.00M$46.46M$49.02M$49.38M
Nucynta Er----------$19.74M$20.68M$21.79M$16.20M$17.05M$15.43M$17.03M---
Nucynta Ir----------$29.09M$29.24M$30.53M$29.27M$30.00M$29.07M$27.97M---
Xtampza----------$30.02M$33.02M$35.41M$30.79M$32.13M$33.56M$31.51M$26.48M$26.02M$25.13M

Collegium Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Belbuca (35.15%), Xtampza ER (32.70%), Nucynta IR (16.76%), Nucynta ER (13.07%), and Symproic (2.32%).

Collegium Pharmaceutical Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
ALKSAlkermes$1.66B$378.14M
PBHPrestige Consumer Healthcare$1.13B$283.55M
PAHCPhibro Animal Health$977.89M$273.16M
PCRXPacira BioSciences$674.98M$168.57M
AMPHAmphastar Pharmaceuticals$593.24M$188.82M
COLLCollegium Pharmaceutical$566.77M$159.30M
ANIPANI Pharmaceuticals$486.82M$148.33M
ITCIIntra-Cellular Therapies$462.18M$175.38M
PROCProcaps Group$409.92M$118.41M
EGRXEagle Pharmaceuticals$316.61M$64.65M
EOLSEvolus$199.72M$60.16M
SSICSilver Spike Investment$11.72M$2.76B
RGCRegencell Bioscience--

COLL Revenue FAQ

What is Collegium Pharmaceutical’s yearly revenue?

Collegium Pharmaceutical's yearly revenue for 2023 was $566.77M, representing an increase of 22.17% compared to 2022. The company's yearly revenue for 2022 was $463.93M, representing an increase of 67.56% compared to 2021. COLL's yearly revenue for 2021 was $276.87M, representing a decrease of -10.69% compared to 2020.

What is Collegium Pharmaceutical’s quarterly revenue?

Collegium Pharmaceutical's quarterly revenue for Q3 2024 was $159.3M, a 9.65% increase from the previous quarter (Q2 2024), and a 16.53% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $145.28M, a 0.24% increase from the previous quarter (Q1 2024), and a 7.18% increase year-over-year (Q2 2023). COLL's quarterly revenue for Q1 2024 was $144.92M, a -3.22% decrease from the previous quarter (Q4 2023), and a 0.11% increase year-over-year (Q1 2023).

What is Collegium Pharmaceutical’s revenue growth rate?

Collegium Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 104.71%, and for the last 5 years (2019-2023) was 91.02%.

What are Collegium Pharmaceutical’s revenue streams?

Collegium Pharmaceutical's revenue streams in c 23 are Nucynta IR, Symproic, Xtampza ER, Belbuca, and Nucynta ER. Nucynta IR generated $108.15M in revenue, accounting 19.08% of the company's total revenue, down -3.49% year-over-year. Symproic generated $16.5M in revenue, accounting 2.91% of the company's total revenue, up 34.47% year-over-year. Xtampza ER generated $177.37M in revenue, accounting 31.30% of the company's total revenue, up 27.79% year-over-year. Belbuca generated $182.1M in revenue, accounting 32.13% of the company's total revenue, up 43.99% year-over-year. Nucynta ER generated $82.65M in revenue, accounting 14.58% of the company's total revenue, up 14.13% year-over-year.

What is Collegium Pharmaceutical’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Collegium Pharmaceutical was Belbuca. This segment made a revenue of $182.1M, representing 32.13% of the company's total revenue.